Assertio therapeutics' development partner gets crl from fda for long-acting cosyntropin

Assertio therapeutics provides regulatory update on long-acting cosyntropin.assertio therapeutics - its development partner got crl from fda for its nda for injectable formulation of long-acting cosyntropin.assertio therapeutics - primary focus of crl relates to fda determination that certain pharmacodynamic parameters were not adequately achieved.
ASRT Ratings Summary
ASRT Quant Ranking